Product Pipeline

Xenon is focused on advancing our ion channel neurology pipeline.

The products within our novel proprietary pipeline – including XEN496, XEN1101 and XEN007 – are aimed at treating neurological disorders, with a particular focus on epilepsy. We intend to pursue a variety of development strategies, such as those focused on using a “precision medicine” approach to address rare pediatric disorders, including KCNQ2 epilepsy, as well as those targeting broader patient populations, such as adult patients with focal epilepsy. We also have promising partnered products within our pipeline, such as NBI-921352 with Neurocrine Biosciences and FX301 with Flexion Therapeutics.

Phase 1
Phase 2
Phase 3


for Epilepsy
X-TOLE Clinical Trial


for MDD
Collaboration with Mount Sinai


for Epilepsy
EPIK Clinical Trial


for Orphan Neurological Indications
Investigator-led Study in CAE


for Epilepsy
Partnered with Neurocrine Biosciences


for Post-Operative Pain
Partnered with Flexion Therapeutics

NAV1.7 Inhibitors

for Pain
Partnered with Genentech

* A physician-led, Phase 2 proof-of-concept study is ongoing to examine XEN007 as an adjunctive treatment in pediatric patients diagnosed with treatment-resistant childhood absence epilepsy (CAE).

Medical Affairs

Learn more about our ongoing clinical trials

View Medical Affairs

See publications related to our clinical development candidates

View Publications

Find out more about collaborating with Xenon

View Partners